Protocol Ledger

NCT07637734 · Phase III · RECRUITING

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Interventional Phase III clinical trial protocol NCT07637734 sponsored by Verrica Pharmaceuticals in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-15 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07637734
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07637734
Protocol FieldVerified Registry Value
NCT IdentifierNCT07637734
Consolidated Lead SponsorVerrica Pharmaceuticals
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2026-06-15
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI